In the preapproval clinical experience with a new medicinal product or its new usages, particularly as therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered ____
a) Adverse Events
b) Serious Adverse Events
c) Adverse Drug Reactions
d) Expected Adverse Events